Top

Published in:

01-02-2012 | Preclinical Study

Daintain/AIF-1 promotes breast cancer cell migration by up-regulated TNF-α via activate p38 MAPK signaling pathway

Authors: Tao Li, Zhiguo Feng, Shaohui Jia, Wei Wang, Zhongxia Du, Ning Chen, Zhengwang Chen

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Abstract

Tumor-associated macrophages can release a vast diversity of growth factors, proteolytic enzymes, cytokines, and inflammatory mediators. Many of these factors are key agents in cancer metastasis. Daintain/AIF-1 is a macrophage-derived inflammatory cytokine which defined a distinct subset of tumor-associated activated macrophages/microglial cells. Previous study demonstrated that daintain/AIF-1 could promote breast cancer proliferation through activating NF-κB/cyclin D1 pathway and facilitate tumor growth. However, the effect of Daintain/AIF-1 on cell migration and cancer metastasis has never been reported. Herein, we used a mimic tumor microenvironment by incubating breast cancer cell lines, MDA-MB-231 and MCF-7 cells, with macrophage-conditioned medium with or without purified daintain/AIF-1 polypeptide to evaluate cell migration. Results indicated that daintain/AIF-1 enhanced the migration of MDA-MB-231 and MCF-7 cells in the manner of TNF-α up-regulation. Further study found that daintain/AIF-1 activates p38 MAPK signaling pathway contributing to up-regulation of TNF-α in MDA-MB-231 and MCF-7 cells. Therefore, this novel daintain/AIF-1-p38-TNF-α pathway and insight into daintain/AIF-1 might have potential benefits in the control of tumor metastasis during cancer therapy.

Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217. doi:10.1016/j.ccr.2005.02.013 PubMedCrossRef

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi:10.1038/Nature07205 PubMedCrossRef

Sethi G, Sung B, Aggarwal BB (2008) TNF: a master switch for inflammation to cancer. Front Biosci 13:5094–5107PubMedCrossRef

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081. doi:10.1093/carcin/bgp127 PubMedCrossRef

Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87:401–406. doi:10.1038/clpt.2009.312 PubMedCrossRef

Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J et al (2008) Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68:1443–1450. doi:10.1158/0008-5472.CAN-07-5704 PubMedCrossRef

Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, Kalomenidis I (2007) Tumor necrosis factor-α promotes malignant pleural effusion. Cancer Research 67:9825–9834PubMedCrossRef

Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F (2007) The inflammatory cytokine TNF-α generates an autocrine tumour-promoting network in epithelial ovarian cancer cells. Cancer Res 67:585–592PubMedCrossRef

10.

Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999) Essential role of tumor necrosis factor α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 59:4516–4518PubMed

11.

Zins K, Abraham D, Sioud M, Aharinejad S (2007) Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 67:1038–1045. doi:10.1158/0008-5472.CAN-06-2295 PubMedCrossRef

12.

Deininger MH, Meyermann R, Schluesener HJ (2002) The allograft inflammatory factor-1 family of proteins. FEBS Lett 514:115–121. doi:10.1016/S0014-5793(02)02430-4 PubMedCrossRef

13.

Iris FJM, Bougueleret L, Prieur S, Caterina D, Primas G, Perrot V, Jurka J, Rodriguez-Tome P, Claverie JM, Dansset J, Cohen D (1993) Dense Alu clustering and a potential new member of the NF kappa B family within a 90 kilobase HLA class III segment. Nat Genet 3:137–145PubMedCrossRef

14.

Autieri MV, Carbone C, Mu AB (2000) Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury. Arterioscler Thromb Vasc 20:1737–1744CrossRef

15.

Nagakawaa Y, Nomoto S, Kato Y, Montgomery RA, Williams GM, Klein AS, Zi Sun (2004) Over-expression of AIF-1 in liver allografts and peripheral blood correlates with acute rejection after transplantation in rats. Am J Transpl 2004:1949–1957CrossRef

16.

Koshiba H, Kitawaki J, Teramoto M, Kitaoka Y, Ishihara H, Obayashi H, Ohta M, Hara H, Adachi T, Honjo H (2005) Expression of allograft inflammatory factor-1 in human eutopic endometrium and endometriosis: possible association with progression of endometriosis. J Clin Endocrinol Metab 90:529–537. doi:10.1210/jc.2004-0871 PubMedCrossRef

17.

Autieri MV, Kelemen SE, Wendt KW (2003) AIF-1 is an actin-polymerizing and Rac1-activating protein that promotes vascular smooth muscle cell migration. Circ Res 92:1107–1114. doi:10.1161/01.Res.0000074000.03562.Cc PubMedCrossRef

18.

Liu S, Tan WY, Chen QR, Chen XP, Fu K, Zhao YY, Chen ZW (2008) Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth. Cancer Sci 99:952–957. doi:10.1111/j.1349-7006.2008.00787.x PubMedCrossRef

19.

Deininger M, Seid K, Meyermann R, Schluesener HJ (1999) Allograft inflammatory factor-1 (AIF-1) is expressed by activated macrophages and microglia in the vessel walls of human and rat brain tumors and rat autoimmune disease. J Vasc Res 36:187–188

20.

Yang ZF, Ho DW, Lau CK, Lam CT, Lum CT, Poon RTP, Fan ST (2005) Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. Int Immunol 17:1391–1397. doi:10.1093/intimm/dxh316 PubMedCrossRef

21.

Chen ZW, Ahren B, Ostenson CG, Cintra A, Bergman T, Moller C, Fuxe K, Mutt V, Jornvall H, Efendic S (1997) Identification, isolation, and characterization of daintain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB rats. Proc Natl Acad Sci USA 94:13879–13884PubMedCrossRef

22.

De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate—implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992PubMedCrossRef

23.

Kuper H, Adami HO, Trichopoulos D (2001) Infections as a major preventable cause of human cancer. J Intern Med 249:61–73CrossRef

24.

Van Kempen LCL, De Visser KE, Coussens LM (2006) Inflammation, proteases and cancer. Eur J Cancer 42:728–734. doi:10.1016/j.ejca.2006.01.004 PubMedCrossRef

25.

Chen X, Kelemen SE, Autieri MV (2004) AIF-1 expression modulates proliferation of human vascular smooth muscle cells by autocrine expression of G-CSF. Arterioscler Thromb Vasc Biol 24:1217–1222PubMedCrossRef

26.

Wu Y, Zhou BP (2010) TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102:639–644. doi:10.1038/sj.bjc.6605530 PubMedCrossRef

27.

Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, Murakami T, Drutskaya LN, Forster I, Clausen BE et al (2005) Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22:93–104. doi:10.1016/j.immuni.2004.11.016 PubMed

28.

Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN (1993) Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177:1391–1398PubMedCrossRef

29.

Bates RC, Mercurio AM (2003) Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14:1790–1800. doi:10.1091/mbc.E02-09-0583 PubMedCrossRef

30.

Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:U102–U108. doi:10.1038/Nature07623 CrossRef

31.

Hugo HJ, Wafai R, Blick T, Thompson EW, Newgreen DF (2009) Staurosporine augments EGF-mediated EMT in PMC42-LA cells through actin depolymerisation, focal contact size reduction and Snail1 induction—a model for cross-modulation. BMC Cancer 9:235. doi:10.1186/1471-2407-9-235 PubMedCrossRef

32.

Yilmaz M, Christofori G (2010) Mechanisms of motility in metastasizing cells. Mol Cancer Res 8:629–642. doi:10.1158/1541-7786.Mcr-10-0139 PubMedCrossRef

33.

Estrela-Lima A, Araujo MS, Costa-Neto JM, Teixeira-Carvalho A, Barrouin-Melo SM, Cardoso SV, Martins-Filho OA, Serakides R, Cassali GD (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 10:256. doi:10.1186/1471-2407-10-256 PubMedCrossRef

34.

Chen JJW, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23:953–964. doi:10.1200/Jco.2005.12.172 PubMedCrossRef

35.

Sica A (2010) Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol 32:153–158PubMed

Title: Daintain/AIF-1 promotes breast cancer cell migration by up-regulated TNF-α via activate p38 MAPK signaling pathway
Authors: Tao Li
Zhiguo Feng
Shaohui Jia
Wei Wang
Zhongxia Du
Ning Chen
Zhengwang Chen
Publication date: 01-02-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1519-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

Incidence and risk factors for axillary web syndrome after breast cancer surgery

Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas

Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer